HLA‐class II haplotype associations with ovarian cancer

Abstract

The development of cancer is a multistep process that is characterized by the accumulation of genetic alterations in cells and changed cellular interactions with the surrounding healthy tissues. The human immune system is believed to be intrinsically involved in this process. The correlation of certain human leukocyte antigen (HLA)-class I and II haplotypes with tumorigenesis is documented in a variety of tumors. However, few data exist on the possible association of specific HLA-class II alleles or haplotypes with ovarian cancer. In our sample of 52 Caucasian patients with primary ovarian carcinoma and 239 female healthy local controls, we observed a significantly increased incidence of the HLA-class II haplotypes DRB1*0301 -DQA1*0501 -DQB1*0201 (p < 0

MHC Class II alleles in ulcerative colitis-associated colorectal cancer

“…The HLA region of chromosome 6 is highly polymorphic with multiple alleles possible for both the HLA-DR and HLA-DQ loci 1 3 4 5. These create minor binding groove variations that may affect a cell’s ability to present exogenous peptides, derived from digestion of viral and bacterial components, to CD4+ T cells 1 3 4 5.…”

“…These genes are highly polymorphic, with the majority of the polymorphisms resulting in functional amino acid changes that can lead to significant variability in an individual’s response to antigens 1 3 4 5. This variability may have particular significance in the colon, which is continuously exposed to antigens from food, chemicals and bacteria, resulting in a constant state of controlled inflammation 5…”

Analysis of HLA-A, HLA-B and HLA-DRB1 alleles in Chinese patients with lung cancer

“…Because of its important role in the immune response and high polymorphism, the HLA system is associated with many diseases. Recently, many papers about the association between HLA and many types of tumor have been published, including cervical cancer (Schiff et al, 2005;Madeleine et al, 2008), leukemia (Dorak et al, 2002;Mundhada et al, 2004;Wu et al, 2007;Yari et al, 2008), gastric cancer (Wu et al, 2002;Quintero et al, 2005), ovarian cancer (Kübler et al, 2006), thyroid cancer (Haghpanah et al, 2009), and breast cancer (Cantú de León et al, 2009). …”

ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139

“…The HLA phenotype of YDOV-139 was A * 24/A * 31, B * 07/B * 35, Cw03 * (09)/w * 07, and DRB1 * 01/ DRB1 * 15, which is unrelated to phenotypes previously reported to show association with cancer development (21,22). The tumor suppressor genes BRCA1 and 2 are known to be involved in DNA repair and maintenance of genetic stability (23,24), and mutation of these genes has been linked to hereditary breast and ovarian cancer.…”